In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Unveiling the Therapeutic Potential of the Second Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link